GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » Net Change in Cash

Abaxis (Abaxis) Net Change in Cash : $-46.1 Mil (TTM As of Mar. 2018)


View and export this data going back to 1992. Start your Free Trial

What is Abaxis Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Abaxis's Net Change in Cash for the three months ended in Mar. 2018 was $-25.8 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2018 was $-46.1 Mil.

Abaxis Net Change in Cash Historical Data

The historical data trend for Abaxis's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis Net Change in Cash Chart

Abaxis Annual Data
Trend Mar09 Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.17 35.53 -18.81 3.63 -46.12

Abaxis Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.58 -0.47 -32.80 12.92 -25.78

Abaxis Net Change in Cash Calculation

Abaxis's Net Change in Cash for the fiscal year that ended in Mar. 2018 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=43.516+-73.437+-16.201+0
=-46.1

Abaxis's Net Change in Cash for the quarter that ended in Mar. 2018

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=6.356+-28.433+-3.7+0
=-25.8

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abaxis Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Abaxis's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Abaxis (Abaxis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » Net Change in Cash
Comparable Companies
NVTA MYGN NSE:LALPATHLAB SZSE:300244 NRC SZSE:300463 SZSE:300685 BEAT TSE:4544 SZSE:300482 SHSE:603127 TSE:4694 NEO SZSE:300406 MEDP OPK QDEL BOM:542650 RDNT CDNA
Traded in Other Exchanges
N/A
Address
Website
http://www.abaxis.com
Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.
Executives
Richard Bastiani director C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr officer: CFO and VP of Finance C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson director, officer: CEO & Board Chairman C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020